First oncolytic virus approved for melanoma immunotherapy

Jonathan Pol; Guido Kroemer; Lorenzo Galluzzi

doi:10.1080/2162402X.2015.1115641

First oncolytic virus approved for melanoma immunotherapy

Jonathan Pol, Guido Kroemer, Lorenzo Galluzzi

Résultats de recherche: Contribution à un journal › Editorial

254 Citations (Scopus)

Résumé

On 2015, October 27th, the US Food and Drug Administration (FDA) has officially approved talimogene laherparepvec (T-VEC, also known as OncoVEX^GM-CSF) for use in melanoma patients with injectable but non-resectable lesions in the skin and lymph nodes. T-VEC (which is commercialized by Amgen, Inc. under the name of Imlygic®) becomes therefore the first oncolytic virus approved for cancer therapy in the US.

langue originale	Anglais
Numéro d'article	e1115641
journal	OncoImmunology
Volume	5
Numéro de publication	1
Les DOIs	https://doi.org/10.1080/2162402X.2015.1115641
état	Publié - 1 janv. 2016

Accès au document

10.1080/2162402X.2015.1115641

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{cfa24f0dcf304c8eaa40273a32de3e78,

title = "First oncolytic virus approved for melanoma immunotherapy",

abstract = "On 2015, October 27th, the US Food and Drug Administration (FDA) has officially approved talimogene laherparepvec (T-VEC, also known as OncoVEXGM-CSF) for use in melanoma patients with injectable but non-resectable lesions in the skin and lymph nodes. T-VEC (which is commercialized by Amgen, Inc. under the name of Imlygic{\textregistered}) becomes therefore the first oncolytic virus approved for cancer therapy in the US.",

keywords = "Granulocyte macrophage colony-stimulating factor, Imlygic{\textregistered}, OPTiM, OncoVEX, T-vec, talimogene laherparepvec",

author = "Jonathan Pol and Guido Kroemer and Lorenzo Galluzzi",

note = "Publisher Copyright: {\textcopyright} 2016, Taylor & Francis Group, LLC.",

year = "2016",

month = jan,

day = "1",

doi = "10.1080/2162402X.2015.1115641",

language = "English",

volume = "5",

journal = "OncoImmunology",

issn = "2162-4011",

number = "1",

}

TY - JOUR

T1 - First oncolytic virus approved for melanoma immunotherapy

AU - Pol, Jonathan

AU - Kroemer, Guido

AU - Galluzzi, Lorenzo

PY - 2016/1/1

Y1 - 2016/1/1

N2 - On 2015, October 27th, the US Food and Drug Administration (FDA) has officially approved talimogene laherparepvec (T-VEC, also known as OncoVEXGM-CSF) for use in melanoma patients with injectable but non-resectable lesions in the skin and lymph nodes. T-VEC (which is commercialized by Amgen, Inc. under the name of Imlygic®) becomes therefore the first oncolytic virus approved for cancer therapy in the US.

AB - On 2015, October 27th, the US Food and Drug Administration (FDA) has officially approved talimogene laherparepvec (T-VEC, also known as OncoVEXGM-CSF) for use in melanoma patients with injectable but non-resectable lesions in the skin and lymph nodes. T-VEC (which is commercialized by Amgen, Inc. under the name of Imlygic®) becomes therefore the first oncolytic virus approved for cancer therapy in the US.

KW - Granulocyte macrophage colony-stimulating factor

KW - Imlygic®

KW - OPTiM

KW - OncoVEX

KW - T-vec

KW - talimogene laherparepvec

UR - http://www.scopus.com/inward/record.url?scp=85046155009&partnerID=8YFLogxK

U2 - 10.1080/2162402X.2015.1115641

DO - 10.1080/2162402X.2015.1115641

M3 - Editorial

AN - SCOPUS:85046155009

SN - 2162-4011

VL - 5

JO - OncoImmunology

JF - OncoImmunology

IS - 1

M1 - e1115641

ER -